These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38902138)

  • 1. The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Scilipoti P; Ślusarczyk A; de Angelis M; Soria F; Pradere B; Krajewski W; D'Andrea D; Mari A; Giudice FD; Pichler R; Subiela JD; Afferi L; Albisinni S; Mertens L; Laukhtina E; Mori K; Radziszewski P; Shariat SF; Necchi A; Xylinas E; Gontero P; Rouprêt M; Montorsi F; Briganti A; Moschini M;
    Eur Urol Oncol; 2024 Dec; 7(6):1293-1302. PubMed ID: 38902138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
    Black PC; Tangen CM; Singh P; McConkey DJ; Lucia MS; Lowrance WT; Koshkin VS; Stratton KL; Bivalacqua TJ; Kassouf W; Porten SP; Bangs R; Plets M; Thompson IM; Lerner SP
    Eur Urol; 2023 Dec; 84(6):536-544. PubMed ID: 37596191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
    Mariappan P; Johnston A; Trail M; Hamid S; Hollins G; Dreyer BA; Ramsey S; Padovani L; Garau R; Enriquez JG; Boden A; Maresca G; Simpson H; Hasan R; Sharpe C; Thomas BG; Chaudhry AH; Khan RS; Bhatt JR; Ahmad I; Nandwani GM; Dimitropoulos K; Makaroff L; Shaw J; Graham C; Hendry D;
    Eur Urol Oncol; 2024 Dec; 7(6):1327-1337. PubMed ID: 38296735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
    Subiela JD; Krajewski W; González-Padilla DA; Laszkiewicz J; Taborda J; Aumatell J; Sanchez Encinas M; Basile G; Moschini M; Caño-Velasco J; Lopez Perez E; Del Olmo Durán P; Gallioli A; Tukiendorf A; D'Andrea D; Yuen-Chun Teoh J; Serna Céspedes A; Pichler R; Afferi L; Del Giudice F; Gomez Rivas J; Albisinni S; Soria F; Ploussard G; Mertens LS; Rajwa P; Laukhtina E; Pradere B; Tully K; Guerrero-Ramos F; Rodríguez-Faba Ó; Alvarez-Maestro M; Dominguez-Escrig JL; Szydełko T; Gomez Dos Santos V; Jiménez Cidre MÁ; Burgos Revilla FJ;
    Eur Urol Oncol; 2024 Dec; 7(6):1367-1375. PubMed ID: 38355375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
    Psutka SP; Veleber S; Siman J; Holt SK; Jannat S; Wright JL; Lin DW; Gore JL; Schade GR; Annen Z; Greenlee H
    Eur Urol Oncol; 2024 Dec; 7(6):1431-1440. PubMed ID: 38653622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of abstinence-based and harm reduction-based interventions in reducing problematic substance use in adults who are experiencing homelessness in high income countries: A systematic review and meta-analysis: A systematic review.
    O'Leary C; Ralphs R; Stevenson J; Smith A; Harrison J; Kiss Z; Armitage H
    Campbell Syst Rev; 2024 Jun; 20(2):e1396. PubMed ID: 38645303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer.
    Guerrero-Ramos F; Boormans JL; Daneshmand S; Gontero P; Kamat AM; Rouprêt M; Vilaseca A; Shariat SF
    Eur Urol Oncol; 2024 Dec; 7(6):1267-1279. PubMed ID: 38849286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study.
    Soria F; Rosazza M; Livoti S; Dutto D; Colucci F; Sylvester RJ; Shariat SF; Babjuk M; Palou J; Gontero P
    Eur Urol Focus; 2024 Jul; 10(4):648-653. PubMed ID: 37923633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration.
    Soria F; Rosazza M; Livoti S; Moschini M; De Angelis M; Giudice FD; Pichler R; Hurle R; Mancon S; Carrion DM; Krajewski W; Mertens LS; D'Andrea D; Mari A; Di Maida F; Dutto D; Colucci F; Casale G; Fertitta G; Laukhtina E; Albisinni S; Pradere B; Teoh JYC; Shariat SF; Briganti A; Kamat AM; Gontero P
    Eur Urol Oncol; 2024 Dec; 7(6):1497-1503. PubMed ID: 38906794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
    Edwards SJ; Karner C; Jhita T; Barton S; Marceniuk G; Yiu ZZN; Wittmann M
    Health Technol Assess; 2024 Jan; 28(4):1-113. PubMed ID: 38343072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Immediate Hyperthermic Intravesical Chemotherapy Following Transurethral Resection of Bladder Tumour (I-HIVEC).
    Wong CH; Ko IC; Leung DK; Yuen SK; Chan SY; Yee SC; Chiu PK; Ng CF; Teoh JY
    Eur Urol Oncol; 2024 Dec; 7(6):1171-1174. PubMed ID: 38806344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis.
    Shabaninejad H; Kenny RP; Robinson T; Stoniute A; O'Keefe H; Still M; Thornton C; Pearson F; Beyer F; Meader N
    Health Technol Assess; 2024 Oct; 28(75):1-75. PubMed ID: 39487741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle.
    Glujovsky D; Pesce R; Miguens M; Sueldo C; Ciapponi A
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD013827. PubMed ID: 38032057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.
    Goldkuhle M; Kreuzberger N; von Tresckow B; Eichenauer DA; Specht L; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD007110. PubMed ID: 39620432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab for maintenance of medically-induced remission in Crohn's disease.
    Gordon M; Sinopoulou V; Akobeng AK; Sarian A; Moran GW
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD012609. PubMed ID: 38372447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.